An investigation of the nature of plasminogen activator inhibitor type-I (PAI-I) to improve upon known small molecule inhibitors [PDF]
, 2019 Plasminogen activator inhibitor type-I (PAI-I ) is a serpin superfamily member protein that acts as the major inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).
Powers, Justin A.
core +1 more source
Pharmacological myeloperoxidase (MPO) inhibition in an obese/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling [PDF]
, 2019 Lifestyle factors are important drivers of chronic diseases, including cardiovascular syndromes, with low grade inflammation as a central player. Attenuating myeloperoxidase (MPO) activity, an inflammatory enzyme associated with obesity, hypertension and
de Boer, Rudolf A +6 more
core +1 more source
Structural and functional analysis of the interaction between vitronectin and the thrombin-antithrombin pair [PDF]
, 2001 Vitronectin is a multifunctional glycoprotein found both in the circulation and in the extracellular matrix. Circulating vitronectin is in monomeric form while matrix and tissue associated vitronectin tend to form multimers. Interacts with a wide variety
Oguz-Ozen, Secil
core +1 more source
Diacetyloxyl derivatization of the fibroblast growth factor inhibitor dobesilate enhances its anti-inflammatory, anti-angiogenic and anti-tumoral activities [PDF]
, 2015 Dobesilate (2,5-dihydroxyphenyl sulfonate, DHPS) was recently identified as the most potent member of a family of fibroblast growth factor (FGF) inhibitors headed by gentisic acid, one of the main catabolites of aspirin.
Javier Angulo +7 more
core +1 more source
Investigations into the fibrinolytic system and haptoglobin types in certain hereditary and acquired haemostatic disorders and the presence of circulating anticoagulants in such states [PDF]
, 1963 I THE FIBRINOLYTIC SYSTEM: A review of the literature is presented together with an evaluation of the present methods for the measurement of its parameters.The methods adopted in the course of this study include (l) the heated fibrin plate for the ...
Kamel, Karim
core
ANIMAL VENOM FOR TREATING BREAST CANCER [PDF]
, 2014 Breast cancer is one of the most common malignancies found in women and is associated with increased mortality in advanced disease. With the use of improved screening techniques and improvisation in treatment, 89% of the women diagnosed with breast ...
Ahluwalia, Sanchita, Shah, Nakul
core
Optimization of Clustering and Database Screening Procedures for Cavbase and Virtual Screening for Novel Antimalarial and Antibacterial Molecules [PDF]
, 2012 Im Zyklus der rationellen Arzneimittelentwicklung werden Affinität und Selektivität von potentiellen Wirkstoffen intensiv erforscht. Da diese beiden Eigenschaften keine lineare Abhängigkeit zueinander aufweisen, führt höhere Affinität nicht ...
Glinca, Serghei
core +1 more source
European Journal of Biochemistry, 2003 Plasminogen activator inhibitor‐1 (PAI‐1) belongs to the serpin family of serine proteinase inhibitors. Serpins inhibit their target proteinases by an ester bond being formed between the active site serine of the proteinase and the P1 residue of the reactive centre loop (RCL) of the serpin, followed by insertion of the RCL into β‐sheet A of the serpin.
Bødker, Julie S. +5 more
openaire +2 more sources
An antibody that targets cell-surface glucose-regulated protein-78 inhibits expression of inflammatory cytokines and plasminogen activator inhibitors by macrophages. [PDF]
J Cell Biochem, 2023 Gunner CB +6 more
europepmc +1 more source
Design, synthesis, and biological evaluation of non-symmetric smal [PDF]
, 2014 Plasminogen activator inhibitor-1 (PAI-1) is a member of the serpin family of proteins, a primary inhibitor of both tissue-type and urokinase-type plasminogen activators in plasma, and is a well-established risk factor in various disease conditions ...
Anumala, Himabindu
core +1 more source